SEOM-GEINO clinical guidelines for high-grade gliomas of adulthood (2022)

Pérez Segura, Pedro; Vilariño Quintela, Noelia; Martínez García, María; Barco Berrón, Sonia del; Gironés i Sarrió, Regina; García Gómez, Jesús; García Castaño, Almudena; Navarro Martín, Luis Miguel; Gallego Rubio, Óscar; Pineda Losada, Estela

doi:http://dx.doi.org/10.1007/s12094-023-03245-y

SEOM-GEINO clinical guidelines for high-grade gliomas of adulthood (2022)

License

Citation

Pérez Segura P, Vilariño Quintela N, Martínez García M, Del Barco Berrón S, Gironés Sarrió, García Gómez J, et al. SEOM-GEINO clinical guidelines for high-grade gliomas of adulthood (2022). Clin Transl Oncol. 2023 Sep;25(9):2634-46. DOI: 10.1007/s12094-023-03245-y

Abstract

High-grade gliomas (HGG) are the most common primary brain malignancies and account for more than half of all malignant primary brain tumors. The new 2021 WHO classification divides adult HGG into four subtypes: grade 3 oligodendroglioma (1p/19 codeleted, IDH-mutant); grade 3 IDH-mutant astrocytoma; grade 4 IDH-mutant astrocytoma, and grade 4 IDH wild-type glioblastoma (GB). Radiotherapy (RT) and chemotherapy (CTX) are the current standard of care for patients with newly diagnosed HGG. Several clinically relevant molecular markers that assist in diagnosis and prognosis have recently been identified. The treatment for recurrent high-grade gliomas is not well defined and decision-making is usually based on prior strategies, as well as several clinical and radiological factors. Whereas the prognosis for GB is grim (5-year survival rate of 5-10%) outcomes for the other high-grade gliomas are typically better, depending on the molecular features of the tumor. The presence of neurological deficits and seizures can significantly impact quality of life.